New Retina Radio by Eyetube

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

Ehsan Rahimy, MD, and Sumit Sharma, MD, examine the unmet needs in wet AMD and DME, from insufficient disease control to injection burden. They explore the emerging role of IL-6 as a driver of both conditions review, review data to support the role that IL-6 plays in both wet AMD and DME pathogenesis.  and discuss EYP-1901 (EyePoint, Inc.), a sustained-release TKI in development for wet AMD and DME.. Phase 2  clinical data from the VERONA and DAVIO 2 trials are reviewed, including visual acuity and anatomic outcomes, and the potential for reduced treatment burden.

What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not yet motivated to pursue treatment.

How have 3 years of real-world experience with complement inhibition changed when and how retina specialists treat GA? In episode 2 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, examine how referral patterns, safety data, and extension study findings have shifted their approach to early treatment. The group then works through a hypothetical case of an active 73-year-old patient with extrafoveal GA and intermediate AMD in the fellow eye, exploring how lesion characteristics, CNV risk counseling, and months-long travel schedules factor into the treatment decision.

Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor into early treatment decisions.

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Omesh P. Gupta, MD, retina specialist at Wills Eye Hospital, and Shane Griffin, MD, MCR, vitreoretinal surgery fellow at the University of California San Diego Shiley Eye Institute, to discuss scleral-fixating secondary IOLs. They share pearls for implantation success, advanced techniques, and tricks for handling complicated cases.

Does retinal capillary non-perfusion reliably predict functional vision loss in DR? And does the answer change how retina specialists treat it? In this episode of New Retina Radio Journal Club with VBS, Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD, discuss a prospective longitudinal cohort study examining the association between retinal sensitivity and perfusion over 2 years in patients with DR.

In this episode of RetinaLIVE, Kourous Rezaei, MD is joined by Lejla Vajzovic, MD, FASRS and Aleksandra Rachitskaya, MD, FASRS to discuss their experiences with UNITY® VCS in vitreoretinal surgery. The conversation covers instrument design, workflow, training and the integration of new technology in clinical practice, offering perspectives on collaboration and adapting to evolving surgical tools.  For Important Product Information, visit unityvcs.com. Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:15, 19:31, 26:25: Compared to CONSTELLATION® Vision System. Based on bench data. 1:47, 2:15, 2:42, 3:19, 9:55: Compared to HYPERVIT 20K 2:15, 2:21, 7:24: Based on bench data. For both 25 Ga and 27 Ga vitrectomy probes. 7:24, 7:54, 18:46: Versus Alcon's Non-Dynamic Stiffener 27+ technology 9:55, 12:21: When the Dynamic Stiffener is fully retracted 16:20: MSLP(4) is 3 times faster than SSLP 23:58: Compared to CONSTELLATION® Vision System. Based on bench data. Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. †IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg.   References: Hypervit Directions for Use. TetraSpot Multi-spot Laser Probe Directions for Use. UNIFEYE Directions for Use. Alcon Data on File, 2024. [REF-24644] Alcon Data on file, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24379] Alcon Data on File, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24576] UNITY VCS and CS User Manual. Alcon Data on File, 2024. [REF-27800] Gerardo GS, Chow DR. Shovel and Cut Technique: Beveled Vitrectomy Probes to Address Diabetic Tractional Retinal Detachments. Retina. 2023. 1;43(7):1207-1208 Berrocal MH. All-probe vitrectomy dissection techniques for diabetic tractional retinal detachments: Lift and shave. Lift and Shave. Retina. 2018 Sep;38 Suppl 1:S2-S4. González-Saldivar G, Chow DR. The Shovel and cut technique: Beveled vitrectomy probes to address diabetic tractional retinal detachments. Retina. Published online ahead of print. doi:10.1097/IAE.0000000000002938. Po-Lin Chen, Yan-Ting Chen, San-Ni Chen, Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy. Plos One. 2021:16(3) Kasi SK, Hsu J, Hariprasad SM. Making the Jump to 27-Gauge Vitrectomy: Perspectives. Ophthalmic Surgery, Lasers and Imaging Retina. 2017;48(6):450-456. doi:10.3928/23258160-20170601-02 James M. Lai, et all. Mechanical Property Comparison of 23-, 25- and 27-gauge Vitrectors Across Vitrectomy Systems. Ophthalmology Retina. 2022. Alcon Data on File, 2024. [REF-09694] Alcon Data on File, 2024. [REF-25374] Alcon Data on File, 2024. [REF-24899] Scarfone HA, Rodriguez EC, Rufiner MG, Riera JJ, Fanego SE, Charles M, Albano R. Vitreous-lens interface changes after cataract surgery using active fluidics and active sentry with high and low infusion pressure settings. J Cataract Refract Surg. 2024 Apr 1;50(4):333-338. doi: 10.1097/j.jcrs.0000000000001359. PMID: 37938025; PMCID: PMC10959530. Liu Y, Hong J, Chen X. Comparisons of the clinical outcomes of Centurion® active fluidics system with a low IOP setting and gravity fluidics system with a normal IOP setting for cataract patients with low corneal endothelial cell density. Front Med (Lausanne). 2023 Nov 23;10:1294808. doi: 10.3389/fmed.2023.1294808. PMID: 38076276; PMCID: PMC10704024. Taiki Kokubun, et al. Verification for the usefulness of normal tension cataract surgery. Hanga Beres, et al. Does low infusion pressure microinsision cataract surgery (LIPMiCS) reduce the frequency of post-occulsion breaks? 2022. 66(2) Rauen MP, Joiner H, Kohler RA, O'Connor S. Phacoemulsification using an Active Fluidics System at Physiologic versus High IOP: Impact on Anterior and Posterior Segment Physiology. J Cataract Refract Surg. 2024 Apr 8. doi: 10.1097/j.jcrs.0000000000001457. Epub ahead of print. PMID: 38595209.   © 2026 Alcon Inc.   04/26   US-UVC-2600054

TKIs are all the rage. But what do the data tell us about their ability to effectively treat wet AMD? Akshay Thomas, MD, outlines findings from DAVIO 2, the phase 2 study assessing the safety and efficacy of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD. And Aaron Lee, MD, MSCI, and Cecelia Lee, MD, MS, recap their Cogan Award Lecture from this year's ARVO annual meeting. Hear how they envision a future of ophthalmic research driven by AI and machine learning—and how they know we can only get there by looking back at where we've been.

In this episode of RetinaLIVE, Christina Weng, MD, MBA, FASRS is joined by Mrinali Gupta, MD, FASRS and Omesh Gupta, MD, MBA for a conversation focused on the evolution of 27-gauge instrumentation in vitreoretinal surgery with the UNITY® VCS platform. The panel discusses their experiences adapting to new tools and techniques. Listeners will hear perspectives on integrating new technology and the ongoing refinement of microsurgical approaches.  For Important Product Information, visit unityvcs.com.Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:27: Compared to CONSTELLATION® HYPERVIT 20K vitrectomy probe Based on bench data 3:52, 4:14, 6:28, 7:33, 7:59: Versus Alcon's Non-Dynamic Stiffener 27+ technology 10:14, 11:33, 12:19: Compared to GRIESHABER® REVOLUTION® Handle References: Alcon Data on File, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24379] Alcon Data on File, 2024. [REF-24576] UNITY Phaco Handpiece – Directions for Use. UNITY VCS and CS User Manual Alcon Data on File, 2020. [REF-09694] Alcon Data on File, 2024. [REF-24644] Alcon Data on File, 2024. [REF-25563] Alcon Data on File, 2024. [REF-25994] Alcon Data on File, 2024. [REF-09956] Alcon Data on File, 2019. [REF-09958] Alcon Data on File, 2021. [REF-02476] Alcon Data on File, 2023. [REF-02478] Alcon Data on FIle, 2023. [REF-04981] Alcon Data on File, 2018. [REF-12829] Alcon Data on File, 2017. [REF-09581] Alcon Data on File, 2018. [REF-09577] Alcon Data on File, 2019. [REF-09576] Alcon Data on File, 2018. [REF-09579] Alcon Data on File, 2023. [REF-09955] Alcon Data on File, 2021. [REF-09951] Alcon Data on File, 2023. [REF-09952] Alcon Data on File, 2023. [REF-09952] Alcon Data on File, 2020. [REF-09954] Finesse Flex Loop Directions for Use. © 2026 Alcon Inc.   04/26   US-UVC-2600052

Centered on the UNITY® VCS platform, this RetinaLIVE episode features Sarwar Zahid, MD, FASRS moderating a discussion with John Kitchens, MD and Matthew Cunningham, MD, FASRS. The panel shares firsthand experiences with UNITY® VCS. Listeners will discover practical insights on how the technology support both seasoned surgeons and fellows. For Important Product Information, visit http://unityvcs.com Featured surgeons are paid Alcon consultants. The views expressed are their own. Disclaimers: 1:52: Based on bench data 3:28: MSLP(4) is 3 times faster than SSLP 8:53, 9:16: For posterior segment surgeries/poster cassette pack. (P

Gaining global consensus on DME needs will dictate the terms of future drug development. Can the findings from the DME AWARE Delphi study help? Baruch Kuppermann, MD, PhD, joins the show to review the findings from a 25-doctor panel of global experts. What did they conclude regarding the unmet needs in DME?

When do symptomatic vitreous floaters warrant surgery, and when is observation sufficient? In this episode of New Retina Radio Journal Club with VBS, host Kyle Kovacs, MD, joins Matthew Starr, MD, and Neda Valikodath, MD, to review a major study on vision-degrading myodesopsias from vitreous floaters. They then debate the risks and value of limited refractive vitrectomy for select patients in real-world settings, and review their protocols for patients who present with floaters. 

Co-hosts David Fell, MD, and Justin C. Muste, MD, sit down with Allen C. Ho, MD, director of Retina Research at Wills Eye Hospital, and Curtis Heisel, MD, MBA, a vitreoretinal surgery fellow at the University of California San Diego, to discuss the gene therapy landscape in retina. They share their journeys in the space, the therapies under investigation, and how fellows can get involved. 

Podcast moderator Lejla Vajzovic, MD, sits down with Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi, to explore how new therapies hold promise for extending treatment efficacy in patients with wet AMD. They touch on various drug delivery platforms, gene therapy, tyrosine kinase inhibitors, and the challenges of drug development and approval. 

Katharine Talcott, MD, and Jorge Fortun, MD, share their approaches to utilizing OCT and other retinal imaging in the clinic and the OR, detailing how OCT plays a role in the workflow of specific patient cases. They emphasize how ZEISS unites diagnostics, data management, and surgery through connectivity. They share real-world case examples for how imaging impacts the day-to-day management of patients and how they treat them.This episode is sponsored by Zeiss.

Are patients with DR at higher risk for TDR, DME, vitreous hemorrhage, or blindness based on race or ethnicity ? Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, about a large retrospective cohort study examining more than 627,000 US patients with DR. The panel examines why Black and Hispanic patients faced significantly higher rates of adverse outcomes at  1 and 5 years after diagnosis and unpacks what confounding variables the study could not capture. They consider what these findings should mean for screening strategies, patient education, and the day-to-day management of high-risk diabetic patients in clinic.

Could GLP-1s originally designed for diabetes and weight loss influence the risk of developing wet AMD? In this episode of New Retina Radio Journal Club with VBS, host Barton Blackorby, MD, is joined by Katharine Talcott, MD, and Hong-Uyen Hua, MD, to discuss a large national cohort study examining the relationship between GLP-1s and AMD. They explore potential biologic mechanisms, how big-data analyses are shaping retina research, and what these findings could mean for future AMD studies.

In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD welcomes Steve Charles, MD, FACS, FICS, FASRS and Maria Berrocal, MD for an in-depth conversation on the evolution of vitreoretinal surgery. The panel discusses the historical context of surgical technology, practical considerations for fluidics and intraoperative control, and the importance of adapting techniques for complex cases. Through real-world examples and expert perspectives, listeners will gain valuable insights into surgical decision-making, efficiency and the future of surgical retinal procedures. For Important Product Information, visit unityvcs.com. Disclaimers: Featured surgeons are paid Alcon consultants. The views expressed are their own. 8:57: Compared to HYPERVIT 20K 10:53: 5,000 cSt sillicone oil through 25 Ga cannulas, 1,000 cSt silicone oil through 25 Ga cannulas, up to 80% faster flow rate, all gauges (23 Ga, 25 Ga and 27 Ga entry system), based on bench data 20:45: Compared to CONSTELLATION® Vision System. Based on bench data. References: Alcon Data on File, 2024. [REF-24615] Alcon Data on File, 2024. [REF-24379] Alcon Data on File, 2024. [REF-24576] UNITY VCS and CS User Manual Alcon Data on File, 2024. [REF-24644] Vasavada V, et al. Real-time dynamic intraocular pressure fluctuations during microaxial phacoemulsification using different aspiration flow rates and their impact on early postoperative outcomes: a randomized clinical trial. Journal of Cataract & Refractive Surgery. 2014:30(8);534-540. Vasavada, AR, et al. Impact of high and low aspiration parameters on postoperative outcomes of phacoemulsification randomized clinical trial. Journal of Cataract & Refractive Surgery. 2010:36(4);588-593. Alcon Data on File, 2024. [REF-24899] Alcon Data on File, 2024. [REF-25374] Alcon Data on File, 2025. [REF-28170] NGENUITY 3D Visualization System User Guide 1.5 Manual. Bergamo VC, Caiado RR, Maia A. Et al, role of vital dyes in chromovirectomy. Asia Pac J Ophthalmol. 2021;10(1):26-38. Alcon Data on File, 2024. [REF-25563] Sponsored by Alcon, Inc. © 2026 Alcon Inc.     02/26     US-UVC-2600032

Co-hosts David Fell, MD, and Justin C. Muste, MD, are joined by Danny Mammo, MD, and Sean Berkowitz, MD, MBA, to talk all things uveitis, including challenging (and rewarding!) cases. They discuss signs of uveitis masqueraders, when to consider a diagnostic vitrectomy, how to manage patients at risk of being lost to follow-up, and ways to manage endophthalmitis.

Katherine E. Talcott, MD, sits down with retina mentors Yoshihiro Yonekawa, MD, and Adrienne W. Scott, MD, to discuss various strategies mentors and programs can implement to better support trainees who hale from diverse economic backgrounds.

How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joined by Matt Starr, MD, and Nita Valikodath, MD, MS, to explore a recent paper that leveraged the power the IRIS Registry to assess real-world outcomes for this important subset of patients. 

Podcast co-hosts David Fell, MD, and Justin Muste, MD, are joined by Joshua H. Uhr, MD, and Arnulfo Garza-Reyes, MD, to share their experiences with scleral buckling. They discuss the utility of buckling for various cases, encircling bands versus elements, and tips for surgical success. 

Join Dr. Nemo Patel, Dr. Matthew Donovan, and Dr. Danny Mammo as they share real-world insights on how the next generation of retina specialists are optimizing their patient care by adopting FDA-approved therapies for appropriate patients. Together, they explore how to navigate patient selection, safety monitoring, and workflow integration—while maintaining efficiency and patient confidence. The conversation highlights how practices are evolving to meet the growing need for GA management, from staff training and patient education to effective collaboration with referring optometrists.Listen in to gain actionable strategies that you can implement in your practice today. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

Are you ready to accelerate your understanding of retina care?Join Dr. Nemo Patel as he speaks with Dr. Patrick Staropoli, a fellow retina specialist and professional race car driver, in an engaging discussion about Geographic Atrophy (GA) secondary to AMD.In this episode, Dr. Staropoli shares how the principles of racing—split-second decision-making, teamwork, and maintaining focus under pressure—influence his approach to treating GA. Together, they'll explore the evolving GA treatment landscape and emphasize the critical role of early detection and timely referral. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

Dr. Nemo Patel is joined by Drs. Sam Minaker and Has Al-khersan, who share lessons learned early in their careers about connecting with patients, setting expectations, and integrating therapy for geographic atrophy (GA) secondary to AMD into their respective practices. Together they address how to discuss complex diseases with patients, involve family members in treatment discussions, and build rapport through empathy and transparency. The conversation also highlights practical approaches for team training, workflow efficiency, and addressing real-world challenges in GA care. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

What types of delays do Stargardt disease patients experience when it comes to diagnosis? And what are the implications for such delays? Alexis Warren, MD, is joined by Jesse Sengillo, MD, and Sruthi Arepalli, MD, to discuss findings from a recent paper quantifying delays in diagnosis and suggesting means by which such delays could be mitigated.

Podcast co-hosts David Fell, MD, and Justin Muste, MD, sit down with Wills Eye fellow Flavius Beca, MD, to discuss the highs and lows of fellowship training, including successful cases of uveitis, clinical pearls for pneumatic retinopexy, and the challenges of treating retinal tears and detachments with vitrectomy and scleral buckling.

How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new survey study comparing perspectives from fellowship program directors and recent graduates on surgical volumes, teaching tools, autonomy, and competency benchmarks. The group explores areas of agreement, gaps in current training, and the push for more systematic assessment models in retina training.

How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dosing strategies that balance durability, efficacy, and adherence for working-age patients—without overpromising outcomes.This editorially independent series is supported with advertising by Regeneron.

How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching from legacy agents to next-generations treatments.  This editorially independent series is supported with advertising by Regeneron.

Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study. Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy. Drs. Sridhar, Runner, and Sheth are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Runner, and Sheth for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice.  Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients and caregivers. Plus, are AREDS supplements an option for GA patients? 

At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and FAF imaging, discusses patient/caregiver education, and the promise of AI tools in caring for GA patients. 

Does antibiotic prophylaxis prior to intravitreal injection affect the risk of endophthalmitis? Join New Retina Radio Journal Club with VBS moderator Alexis Warren, MD, as she and panelists Sruthi Arepalli, MD, and Jesse Sengillo, MD, sort out the details of a recent paper and discuss whether these findings alter clinical practice. 

How do you decide when GA patients are ready for complement inhibition—and how do you keep them on therapy in the real world? In episode 3 of The Nuts and Bolts of GA Therapy, moderator Charles Wykoff, MD, PhD, speaks with Kenneth Fan, MD, MBA, and Sruthi Arepalli, MD, about early vs conservative initiation, nuanced counseling on expectations and safety, and how imaging informs treatment decisions. Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.

What do GLP-1 receptor agonists mean for the future of retinal disease? Aleksandra Rachitskaya, MD, joins us to review the ever-evolving data on the relationship between retinal disease and GLP-1 RA use. Could these drugs protect against the development of retinal disease? And Julia Haller, MD, explains her vision of what the future of retina looks like. Who needs to be included in the crafting of best practices to ensure that retina specialists offer the highest quality care? Join us on this episode to find out. 

Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME.  And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025. 

The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offered a survey of developmental projects in dry AMD. What should we look forward to? And Michel Michaelides, MD, shares details from the DRAGON study, which examined the safety and efficacy of tinlarebant (Belite Bio) for the treatment of Stargardt disease. Could a once-daily oral tablet lead to positive outcomes for patients? Listen to the episode to learn more.

How do you create clear, durable treatment plans for real-world GA patients? In episode 2 of The Nuts and Bolts of GA Therapy, host Charles Wykoff, MD, PhD, joins Hasenin Al-khersan, MD, and Nakul Singh, MD, to dissect real-world cases and discuss choosing monthly or EOM week dosing regimens, engaging caregivers, and reconciling clinical trial data with real-world experiences.